Needham Reiterates Buy on Ionis Pharmaceuticals, Maintains $60 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a 'Buy' rating on Ionis Pharmaceuticals (NASDAQ:IONS) and maintained a price target of $60.
September 27, 2023 | 8:16 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer has reiterated a 'Buy' rating on Ionis Pharmaceuticals and maintained a price target of $60.
The reiteration of a 'Buy' rating by a reputable analyst like Joseph Stringer from Needham is a positive signal for Ionis Pharmaceuticals. The maintained price target of $60 indicates that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100